Neuroendocrine and behavioral effects of repetitive transcranial magnetic stimulation in a psychopathological animal model are suggestive of antidepressant-like effects.

Max Planck Institute of Psychiatry, Munich, Germany.
Neuropsychopharmacology (Impact Factor: 7.83). 05/2001; 24(4):337-49. DOI: 10.1016/S0893-133X(00)00191-3
Source: PubMed

ABSTRACT The neuroendocrine and behavioral effects of repetitive transcranial magnetic stimulation (rTMS) were investigated in two rat lines selectively bred for high and low anxiety-related behavior. The stimulation parameters were adjusted according to the results of accurate computer-assisted and magnetic resonance imaging-based reconstructions of the current density distributions induced by rTMS in the rat and human brain, ensuring comparable stimulation patterns in both cases. Adult male rats were treated in two 3-day series under halothane anesthesia. In the forced swim test, rTMS-treatment induced a more active coping strategy in the high anxiety-related behavior rats only (time spent struggling; 332% vs. controls), allowing these animals to reach the performance of low anxiety-related behavior rats. In contrast, rTMS-treated low anxiety-related behavior rats did not change their swimming behavior. The development of active coping strategies in high anxiety-related behavior rats was accompanied by a significantly attenuated stress-induced elevation of plasma corticotropin and corticosterone concentrations. In summary, the behavioral and neuroendocrine effects of rTMS of frontal brain regions in high anxiety-related behavior rats are comparable to the effects of antidepressant drug treatment. Interestingly, in the psychopathological animal model repetitive transcranial magnetic stimulation induced changes in stress coping abilities in the high-anxiety line only.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Anxiety disorders rank among the most frequent psychiatric disorders. Effective psychotherapeutic and psychopharmacological interventions exist, although a considerable number of patients does not respond to standard interventions. Repetitive transcranial magnetic stimulation (rTMS) is capable of modulating cortical activity locally and non-invasively. Therefore, rTMS is discussed as a possible alternative treatment approach in psychiatric disorders. The present paper aims to provide a systematic review of randomised controlled studies, open studies, and case reports examining the potential therapeutic effects of rTMS in anxiety disorders. Overall, these studies suggest beneficial effects of rTMS on anxiety symptoms. Nevertheless, larger randomised controlled studies are warranted to allow a more comprehensive evaluation of the therapeutic efficacy of rTMS in anxiety disorders.
    Fortschritte der Neurologie · Psychiatrie 10/2013; 81(10):550-560. · 0.85 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To examine the evidence for therapeutic effect of fast frequency repeated transcranial magnetic stimulation (stimulation at >1 Hz; FF-rTMS) on depression. Method: All available information published in English was considered. Results: A large body of animal studies indicates that FF-rTMS has the capacity to influence behaviour and biochemical actions, including the regulation of gene expression, in a manner similar to that of electroconvul- sive shock (ECS) and antidepressant medication. There have been eight blind sham controlled studies. In one, the active stimulus may have been inadequate. In another, the sham may have been active. The remaining six studies all showed a significant antidepressant action for the active treatment. Two blind comparisons of FF- rTMS and ECT also indicate a useful antidepressant action for TMS. Conclusion: The evidence strongly supports an antidepressant effect for FF-rTMS. The next step is to increase the efficacy of this treatment. That may involve increasing the dose (number of pulses and/or intensity) and number of treatment sessions (German J. Psychiatry 2001; 4:43-50).
  • Fortschritte der Neurologie · Psychiatrie 08/2009; 77(08):432-443. · 0.76 Impact Factor

Full-text (4 Sources)

Available from
May 15, 2014